Cognition Therapeutics In...

0.42
0.03 (7.12%)
At close: Apr 02, 2025, 3:59 PM
0.40
-3.56%
After-hours: Apr 02, 2025, 07:56 PM EDT
7.12%
Bid 0.39
Market Cap 25.83M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -0.86
PE Ratio (ttm) -0.48
Forward PE -1.23
Analyst Buy
Ask 0.41
Volume 324,509
Avg. Volume (20D) 1,596,505
Open 0.38
Previous Close 0.39
Day's Range 0.38 - 0.42
52-Week Range 0.34 - 2.95
Beta 1.03

About CGTX

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinica...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 8, 2021
Employees 25
Stock Exchange NASDAQ
Ticker Symbol CGTX
Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for CGTX stock is "Buy." The 12-month stock price forecast is $6.5, which is an increase of 1459.50% from the latest price.

Stock Forecasts
3 months ago
+9.31%
Cognition Therapeutics shares are trading higher a... Unlock content with Pro Subscription
3 months ago
+27.5%
Cognition Therapeutics shares are trading higher after the company announced topline results which met its primary endpoint of safety and tolerability from its exploratory Phase 2 SHIMMER study.